MPNs

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

A groundbreaking study reveals rusfertide's potential to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient quality of life.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.

Luspatercept significantly improved red blood cell transfusion independence duration and overall survival in ESA-naive, lower-risk MDS patients vs epoetin alfa.

During a live event, Christopher Benton, MD, discussed treatment of myelodysplastic syndromes like luspatercept and imetelstat as alternatives to ESAs.

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use of ruxolitinib to treat myelofibrosis.

Douglas A. Tremblay, MD, discusses the importance of quality-of-life data from treating patients with polycythemia vera with ropeginterferon alfa-2b-njft.

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients with polycythemia vera.

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.

Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

Hany Elmariah, MD, discusses dose-limiting toxicities of fedratinib in a phase 1 study exploring the drug in patients with myeloproliferative neoplasms after HCT.

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.

The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with myelodysplastic syndromes.

Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes diagnosis.

Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY study.

The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.